News

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.

Many patients present to rheumatologists with arthralgia months or years before they are diagnosed with rheumatoid arthritis. Test your knowledge on progression of arthralgia to rheumatoid arthritis with this quiz.

Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.

Presented at ASRS 2023, results suggest the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with DME.

This approval is the first for an FLT3 inhibitor and it's specifically indicated for patients who have FLT3-ITD.

Dr. Hahn discusses an anchored matching-adjusted indirect comparison in patients with geographic atrophy, suggesting a greater reduction in observed lesion growth with monthly pegcetacoplan versus avacincaptad pegol.

This analysis of Medicare beneficiaries over age 71 suggests the importance of discrete severity measures of hearing loss in older adults, as opposed to binary hearing loss terminology.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

This interview segment with Dr. Kidon featured a discussion about her views on current research in the immunotherapy and food allergy space, as well as her views on the future.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Presented at ASRS 2023, study data suggest aflibercept 8 mg provided greater therapeutic benefit, an extended injection interval, and equivalent safety versus aflibercept 2 mg in eyes with nAMD.

After restrictions, the number of youth more than 1 hour away from a clinic almost doubled to 50%, indicating that half of all youths face increased travel times to access essential gender-affirming care.

RiVive is the second nonprescription naloxone product approved by the FDA, signaling a proactive effort to increase accessibility and consumer availability of life-saving medication.

Dr. Kidon spoke in this interview segment regarding a recent immunotherapy product she and her team have been focused on for patients with peanut allergies.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

This interview with Dr. Kidon featured a discussion regarding Kidon’s current peanut allergy research and views on recent developments in the field.

However, the meta-analysis of patients treated with ranibizumab suggests a similar proportion of patients achieved DME resolution, regardless of baseline DR severity, by month 24.

Most (73%) patients surveyed expressed they sought to completely stop or never start using opioids for their chronic pain.

The study presents a machine learning algorithm utilizing ECG data during CPAP titration that can effectively forecast sleep apnea events.

A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

The FDA has announced Abiomed has initiated a recall of all left-sided Impella pumps, citing inadequate instructions for use as it pertains to precautions to take with patients who have undergone TAVR.

This data on a large racial and ethnic minority cohort indicated that low melanoma incidence and detection rates and more aggressive nature of cancer shows the need for greater attention.